Schering-Plough Corp. apparently is allergic to anothercompany’s attempts to horn in on profits generated by its top-sellingClaritin allergy drug.
That’s why it filed a patent infringement suit in federal court inWilmington against Copley Pharmaceuticals Inc. last week over Copley’sbid to sell a generic version of Claritin, which generated $2.3 billionin sales in 1998, making Claritin the world’s best-sellingantihistamine.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
